Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …

With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …

Background Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas are malignant brain
tumors that cause considerable disability and premature death. Vorasidenib, an oral brain …

Background The combination of ivosidenib—an inhibitor of mutant isocitrate dehydrogenase
1 (IDH1)—and azacitidine showed encouraging clinical activity in a phase 1b trial involving …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …

Background Enasidenib is an oral inhibitor of mutant isocitrate dehydrogenase-2 (IDH2)
proteins. We evaluated the safety and activity of enasidenib plus azacitidine versus …

Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options,
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …

Purpose: To evaluate efficacy and safety of venetoclax+ azacitidine among treatment-naïve
patients with IDH1/2-mutant (mut) acute myeloid leukemia (AML). Patients and Methods …

Metabolic inhibitors have been used in oncology for decades, dating back to antimetabolites
developed in the 1940s. In the past 25 years, there has been increased recognition of …

Reversible, spatial, and temporal regulation of metabolic reprogramming and epigenetic
homeostasis are prominent hallmarks of carcinogenesis. Cancer cells reprogram their …